Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update

3) $(54,529) $(22,170) $(114,729)

Basic and

diluted net

loss per

share $(0.68) $(0.34) $(1.86) $(0.80)






in the


of basic



net loss

per share 30,022 27,797 29,273 27,776




(in thousands, except share and per share data)


September 30, December 31,

2008 2007


Current assets:

Cash and cash equivalents $20,374 $43,258

Prepaid expenses and other current assets 1,683 991

Total current assets 22,057 44,249

Property and equipment, net 728 689

Intellectual property, net 55 58

Other non-current assets 1,195 600

Total assets $24,035 $45,596


Current liabilities:

Accounts payable $6,203 $1,747

Accrued expenses 8,793 2,218

Other current liabilities 87 70

Total current liabilities 15,083 4,035

Other non-current liabilities 426 492

Series A redeemable preferred stock 11 11

Total liabilities 15,52

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
(Date:10/7/2015)... Calif. , Oct. 7, 2015  ChromaDex ... wellness and nutritional ingredients that creates science-based solutions ... sports nutrition, and pharmaceutical products, today announced that ... , CEO and Founder, is now available for ...   -->   ...
(Date:10/7/2015)... , Oct. 7, 2015  October is National Liver ... has committed to donating a portion of its October ... and hepatology practices. ... in a variety of ways; whether it is by ... world, collaborating with researchers in different disease and investigation ...
(Date:10/7/2015)... ... October 07, 2015 , ... Park Systems , ... Coatings to provide a comprehensive overview of the innovations in smart coatings using ... . This webinar will be given by Professor Roberto Advincula, professor with ...
(Date:10/7/2015)... ... October 07, 2015 , ... Tunnell Consulting , Inc. ... the Operational and Process Improvement practice. He brings to his role more than ... “I am delighted that Dr. Matzmorr is joining our team,” said Dr. Philippe Cini, ...
Breaking Biology Technology:
... Following the,establishment of their Industrial Management Board, ... is happy to announce its,official launch event to ... of M.B.N Nanomaterialia, the board members Mr Manfred ... Andrea Reinhardt of microTEC,look forward to a very ...
... Fame Coach Jim Calhoun Credits Early Diagnosis with ... two of AdvaMed 2007:,The MedTech Conference will highlight how ... technology as well as speakers on the,diversity and strength ... conference runs Oct. 1 through Oct. 3., Co-writing ...
... October 2 - Management and Distinguished ... Development Programs, as Well as on,the microRNA Field ... a global leader in,microRNA-based diagnostics and therapeutics, announced ... and their significant potential in cancer,treatment and other ...
Cached Biology Technology:
(Date:9/30/2015)... GARDENS, Fla. , Sept. 30, 2015  The ... this month issued another key ruling in favor of ... determination that Korean fingerprint scanner company Suprema and its ... Act of 1930, a trade provision that declares it ... import trade, by infringing two of Crossmatch,s patents, the ...
(Date:9/28/2015)... 28, 2015  The monitoring of vital signs, ... temperature, is an essential component of patient assessment. ... deterioration in a patient,s condition. However, in general ... typically taken during routine observation rounds only once ... deteriorates between these observation rounds, the warning signs ...
(Date:9/24/2015)...  EyeLock LLC, a market leader of iris-based identity ... latest technology in Booth #602 at next week,s ASIS ... EyeLock,s iris authentication technology provides an unprecedented level ... it the most proven way to authenticate one,s identity ... deliver a fast and friendly user experience to identify ...
Breaking Biology News(10 mins):
... tissues into mice, researchers report in the November Cell ... normal and obese mice. The findings suggest that the hormone ... insulin resistance and type 2 diabetes. , Insulin resistance, in ... sugar (glucose) levels, is a precursor to diabetes. ...
... Cancer Symposium features the latest findings in laboratory, translational ... on new and promising therapeutic approaches, as well as ... To help you take the best advantage of ... you to visit to view the ...
... N.Y. (Mon., Nov. 3, 2008) Understanding the ... tissues requires experimental systems that allow for the study ... laboratory. This month,s issue of Cold Spring ... with detailed instructions for setting up these experimental culture ...
Cached Biology News:
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
DDO Immunogen: DDO (NP_003640, 270 a.a. ~ 370 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Arginine vasopressin receptor (AVP-V2), rat. The peptide used for immunization has no significant similarity with AVP V1a or V1b receptors....
Biology Products: